Brief: Paradigm Biopharmaceuticals Posts HY Net Loss Attributable A$23.2 Million
27/02/2026 01:48
Feb 27 (Reuters) - Paradigm Biopharmaceuticals Ltd PAR.AX: HY NET LOSS ATTRIBUTABLE A$23.2 MILLION HY REVENUE FROM CONTINUING ACTIVITIES A$284,055 Further company coverage: PAR.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Paradigm Biopharmaceuticals
See all newsBrief: Paradigm Biopharmaceuticals Says Board Initiates Voluntary Administration
Brief: Paradigm Biopharmaceuticals Seeks Trading Halt
Australia's Paradigm Biopharmaceuticals slips on discounted placement
Brief: Paradigm Biopharmaceuticals Says Co Completes A$14 Mln Placement
Brief: Paradigm Biopharmaceuticals Requests Trading Halt